ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

VX-828

A development code.

Its studies are mostly in Cystic Fibrosis, led by Vertex Pharmaceuticals.

Furthest: phase 1, since Nov 23, 20232 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Vertex Pharmaceuticals20 open or runningphase 1since Nov 23, 2023Nov 23, 2023none ahead

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Nov 23, 2023First study: phase 1 study in Cystic FibrosisFirst studyNCT06154447 · 165 enrolled · United States
  2. Feb 28, 2025Phase 1 study in Cystic FibrosisNCT06861413 · 68 enrolled · United States

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 2 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06861413Cystic Fibrosis · United States1CompletedMay 5, 202568
NCT06154447Cystic Fibrosis · United States1CompletedJul 10, 2026165

How it is read

Names in the registry

  • “VX-828”, 4 entries

Codes read as this program: VX828.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.